Skip to main content

Day: April 29, 2021

Osisko Metals Closes C$6 Million Private Placement of Flow-Through Shares

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, April 29, 2021 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Corporation” or “Osisko Metals“) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce that it has closed its previously-announced brokered private placement, pursuant to which the Corporation sold an aggregate of 12,000,000 common shares of the Corporation that will qualify as “flow-through shares” (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) (“Flow-Through Shares“) at a price of C$0.50 per Flow-Through Share for aggregate gross proceeds of C$6,000,000, including the exercise in full of the agent’s option (the “Offering“). The Offering was led by Haywood Securities...

Continue reading

Šiaulių bankas will hold an Investor Conference Webinar to introduce the financial results for 1Q 2021 and recent developments

Šiaulių Bankas AB, company code 112025254, address of the head office Tilžės str. 149, Šiauliai, Lithuania. AB Šiaulių bankas invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the May 5, 2021 at 4 pm (EET). The presentation will be held in English. The webinar will be hosted by Vytautas Sinius, CEO and Donatas Savickas, CFO who will introduce the Bank’s financial results for the 1 quarter of 2021 and recent developments, as well participants questions will be answered. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until May 4 to emilija.ivanauskaite@nasdaq.com. How to join the webinar? To join the webinar, please register via following link:https://attendee.gotowebinar.com/register/1038464957773628427....

Continue reading

Robex: Outstanding 2020 Balance Sheet, Operating Income Up 126% and Mine Life Extended to Over 10 Years

QUEBEC CITY, April 29, 2021 (GLOBE NEWSWIRE) — Robex Resources Inc. (“Robex“, “the Group” or “the Company“) (TSXV: RBX/FWB: RB4) is pleased to publish their financial results for the year ending December 31, 2020 and their production results for the first quarter of 2021. All amounts are in Canadian dollars (CAD). Highlights for the Year 202022% INCREASE IN REVENUEGold sales of $120.8 million compared to $99.2 million in 2019.126% INCREASE IN OPERATING INCOMEOperating income of $48.5 million compared to $21.4 million in 2019, including respectively $20.9 million and $31.6 million of depreciation and amortization of tangible assets.28% INCREASE IN CASH FLOWS FROM OPERATING ACTIVITIESiCash flows from operating activitiesi of $65.1 million or $0.111 per shareii compared to $51 million or...

Continue reading

Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results

Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress in July Completed $245 million upsized public offering of stock Presented positive preclinical data from αvβ8 program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models WALTHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2021. Recent Highlights and OutlookExpanded research and development...

Continue reading

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the first quarter ended March 31, 2021, after the market close on Thursday, May 13, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, May 13th to discuss the financial results and recent corporate highlights. To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13718897. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations....

Continue reading

VVC Exploration Adds New Property in Colorado, Further Growing Helium Portfolio

TORONTO, April 29, 2021 (GLOBE NEWSWIRE) — VVC Exploration Corporation (“VVC” or the “Company“) (TSX-V:VVC) announces the addition of a new gas property in its wholly owned subsidiary, Plateau Helium Corporation (“PHC”), a Wyoming corporation. The transaction bolsters VVC’s helium portfolio and its ability to capitalize on the growing demand for helium, driven by increased global usage. The property, known as the Syracuse Extension 1, was purchased at a nominal cost and a commitment to commence production, with the seller retaining a 2% royalty in the property. In addition to the 2% royalty, standard industry royalties of 12.5% are payable to arm’s length land owners from the proceeds of any production. PHC owns a 100% operated working interest in the Syracuse Extension 1 lease subject...

Continue reading

ORBCOMM Announces First Quarter 2021 Results

– Total Revenues of $63.7 Million, In Line with Guidance –– 87,000 Devices Shipped Drives Product Sales Growth –– Company Adds 50,000 Net Subscribers in Q1 Bringing Total Subscribers to 2.28 Million – ROCHELLE PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) — ORBCOMM Inc. (NASDAQ: ORBC), a global provider of Internet of Things (IoT) solutions, today announced financial results for the first quarter ended March 31, 2021. The following financial highlights are in thousands of dollars and unaudited.  Three Months Ended  March 31,  2021   2020Recurring Service Revenues $ 36,241     $ 39,853  Other Service Revenues   1,509       671  Total Service Revenues   37,750       40,524  Product Sales   25,945       25,655  Total Revenues   63,695       66,179  Net Loss Attributable to ORBCOMM Inc. Common Stockholders   (10,574 )     (6,975 )Adjusted...

Continue reading

Vaxart to Present at the World Vaccine Congress Washington 2021

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021. Dr. Tucker’s presentation titled, “Vaxart oral COVID-19 vaccine; hold the ice and the needles,” will provide insight into the Company’s response and approach to addressing the COVID-19 pandemic with a room temperature oral tablet vaccine that is potentially protective against new and emerging COVID-19 strains. Presentation details are as follows:Title: Vaxart oral COVID-19 vaccine; hold the ice and the needlesTrack:...

Continue reading

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its novel implantable subcutaneous product and its use in the prevention of psychedelic drug diversion. LSD and psilocybin microdosing are currently in multiple ongoing clinical trials.  One major overlooked issue is the possibility of the patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose or resale of the drugs to someone other than the patient.  BetterLife’s invention has solved this problem by use of an implant administered...

Continue reading

Apria to Announce First Quarter 2021 Financial Results

INDIANAPOLIS, April 29, 2021 (GLOBE NEWSWIRE) — Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today that it will release fiscal first quarter 2021 financial results on Thursday, May 13, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5247226; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Apria Apria is a leading...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.